This review provides a comprehensive overview of the interplay between vascular stability, CBF regulation, and vascular inflammation in the context of the BBB, with a particular emphasis on the dysfunction of these mechanisms in the pathophysiology of neurodegenerative diseases such as AD, PD, ALS, and MS
It works by modulating innate immune responses, activating macrophages in a way that promotes immune regulation rather than unchecked inflammation
The single most important clinical datum: as of January 2025, no randomized controlled trial of BPC-157 in humans has been registered as completed with results posted on ClinicalTrials.gov for any indication, meaning every dose a patient takes is an unmonitored human experiment with no comparator arm and no systematic safety follow-up
Warm environments can promote bacterial and fungal growth, posing health risks upon consumption
Higher Therapeutic Doses IV administration allows for higher doses of glutathione to be introduced safely into the body, achieving therapeutic levels that would be difficult to reach with oral forms
